Risk factors
Cognition Therapeutics (CGTX) risk factors
Item 1A of every Cognition Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors78 risks3 new4 dropped10 reworded
New risks address clinical-data privacy limits, artificial intelligence, and uncertainty over Securities Act litigation forums.
Filed Mar 26, 2026 - FY2024 10-K risk factors79 risks
Cognition Therapeutics is an early-stage biopharmaceutical company dependent on the success of its lead product candidate, zervimesine, for Alzheimer's and other diseases. The company faces significant financial risks, including net losses, going concern doubts, and potential Nasdaq delisting due to low stock price. Operations rely heavily on external capital raising, non-dilutive NIA grants, and successful clinical trial execution.
Filed Mar 20, 2025